Please visit answersincme.com/860/102769007-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aiwu Ruth He, MD, PhD and Mehmet Akce, MD. In this activity, experts in hepatocellular carcinoma (HCC) discuss how the current and emerging clinical evidence for immune checkpoint inhibitor (ICI)–based regimens can elevate personalized care across disease stages, now and into the future. Upon completion of this activity, participants should be better able to: Evaluate the clinical evidence supporting immune checkpoint inhibitor (ICI)–based regimens for the treatment of hepatocellular carcinoma (HCC) across disease settings; Differentiate available ICI-based combination regimens to inform appropriate frontline treatment selection for patients with unresectable HCC; Apply evidence-based strategies to manage immune-related and regimen-specific toxicities associated with ICI-based regimens in patients with HCC; and Design long-term, personalized treatment plans that integrate patient- and disease-related factors into decision-making for HCC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related